Roche licenses blood-cancer antibody drug SIM0660 from Simcere
Roche agreed to pay $75.0 million upfront for exclusive global rights to develop, manufacture and commercialize SIM0660, an antibody targeting B-cell malignancies, under a licensing deal with Simcere Pharmaceutical.
Roche has struck a licensing agreement with China’s Simcere Pharmaceutical for the development of a blood-cancer drug. Under the deal, Roche will pay $75.0 million upfront for exclusive global rights to develop, manufacture and commercialize SIM0660, an antibody targeting B-cell malignancies.